IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: These observations have led to suggestions that IFNα maintenance therapy after TKI stop could be a strategy to improve TFR rates [38], an approach that is currently under investigation in the ENDURE-CML trial (https://clinicaltrials.gov/ct2/show/NCT03117816), with the IFN + TKI combination trials TIGER (nilotinib + IFN) and BOSUPEG (bosutinib + IFN) also underway.